Cas No.: | 461443-59-4 |
Chemical Name: | 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid |
Synonyms: | AK-602;GW 873140;ONO-4128 |
SMILES: | CCCCN1C2(CCN(CC3=CC=C(C=C3)OC4=CC=C(C(O)=O)C=C4)CC2)C(=O)N[C@H]([C@H](O)C5CCCCC5)C1=O |
Formula: | C33H43N3O6 |
M.Wt: | 577.722 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Aplaviroc (GSK-873140;GW 873140;AK-602;ONO-4128) is a potent, noncompetitive, allosteric antagonist of the CCR5 receptor with pKb of 8.6; blocks the calcium response effects of CCR5 activation by CCL5, and potently blocks in vitro the infection of R5-tropic HIV-1 (R5-HIV-1) at subnanomolar IC50.HIV InfectionPhase 3 Discontinued |